Background: More and more chronic kidney disease (CKD) patients
are accompanied with hyperuricaemia. As is known, hyperuricaemia is an
independent hazard of both cardiovascular diseases (CVD) and chronic kidney
diseases. We aim at identifying Single Nucleotide Polymorphism (SNP) difference
of hURAT1 (rs7932775) and ABCG2 (rs3825016) on CKD patient with hyperuricemia
and/or gout. Methods:All forty-two CKD patients were divided into two
groups: hyperuricemia, and control group. 24 hours urine sample and serum were prepared for testing
biochemistry parameters. The polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method is used to analyze hURAT1 and ABCG2 single nucleotide polymorphisms in
different groups. Results: 17 patients have CT SNP of hURAT1 (rs7932775) and 13 patients have CT SNP
of ABCG2 (rs3825016) in hyperuricemia group, while only 5 persons and 6 persons
have the same mutations in control group respectively. 7 patients have CT SNP
of both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group, while
only 2 persons have the same mutations in control group. CT mutation rates of hURAT1(rs7932775) and ABCG2
(rs3825016) in hyperuricemia group were 60.7%(17/28) and 50%(13/28) respectively, higher than that of control
group (35.7%(5/14)
and 42.8%
References
[1]
Srivastava, A., Kaze, A.D., Mcmullan, C.J., et al. (2018) Uric Acid and the Risks of Kidney Failure and Death in Individuals with CKD. American Journal of Kidney Diseases, 71, 362-370. https://doi.org/10.1053/j.ajkd.2017.08.017
[2]
Li, C.C., Chien, T.M., Wu, W.J., et al. (2018) Uric Acid Stones Increase the Risk of Chronic Kidney Disease. Urolithiasis, 1-5.
https://doi.org/10.1007/s00240-018-1050-1
[3]
Garofalo, C., De Stefano, T., Vita, C., et al. (2018) Hyperuricaemia and Chronic Kidney Disease. Giornale italiano di nefrologia, 35, No. 1.
[4]
Johnson, R.J., Bakris, G.L., Borghi, C., et al. (2018) Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. American Journal of Kidney Diseases, 71, 851-865. https://doi.org/10.1053/j.ajkd.2017.12.009
[5]
Dalbeth, N., Stamp, L.K. and Merriman, T.R. (2017) The Genetics of Gout: Towards Personalised Medicine? BMC Medicine, 15, 108.
https://doi.org/10.1186/s12916-017-0878-5
[6]
Major, T.J., Dalbeth, N., Stahl, E.A., et al. (2018) An Update on the Genetics of Hyperuricaemia and Gout. Nature Reviews Rheumatology, 14, 341-353.
https://doi.org/10.1038/s41584-018-0004-x
[7]
Merriman, T. (2017) Genomic Influences on Hyperuricemia and Gout. Rheumatic Disease Clinics of North America, 43, 389-399.
https://doi.org/10.1016/j.rdc.2017.04.004
[8]
Xu, L., Shi, Y., Zhuang, S., et al. (2017) Recent Advances on Uric Acid Transporters. Oncotarget, 8, 100852-100862. https://doi.org/10.18632/oncotarget.20135
[9]
Jiri, M., Zhang, L., Lan, B., et al. (2016) Genetic Variation in the ABCG2 Gene Is Associated with Gout Risk in the Chinese Han Population. Clinical Rheumatology, 35, 159-163. https://doi.org/10.1007/s10067-015-3105-9
[10]
Tan, P.K., Liu, S., Gunic, E., et al. (2017) Discovery and Characterization of Verinurad, a Potent and Specific Inhibitor of URAT1 for the Treatment of Hyperuricemia and Gout. Scientific Reports, 7, 665.
https://doi.org/10.1038/s41598-017-00706-7
[11]
Cho, S.K., Kim, S., Chung, J.Y., et al. (2015) Discovery of URAT1 SNPs and Association between Serum Uric Acid Levels and URAT1. BMJ Open, 5, e9360.
https://doi.org/10.1136/bmjopen-2015-009360
[12]
Sun, H., Qu, Q., Qu, J., et al. (2015) URAT1 Gene Polymorphisms Influence Uricosuric Action of Losartan in Hypertensive Patients with Hyperuricemia. Pharmacogenomics, 16, 855-863. https://doi.org/10.2217/pgs.15.52
[13]
Chen, C.J., Tseng, C.C., Yen, J.H., et al. (2018) ABCG2 Contributes to the Development of Gout and Hyperuricemia in a Genome-Wide Association Study. Scientific Reports, 8, 3137. https://doi.org/10.1038/s41598-018-21425-7
